Benchmark against your competition
Understand how AI crawlers access your site
See where AI gets info about you
Track the queries mentioning your brand
Own your AI narrative
Add GEO to your service offerings
Get recommended in shopping queries
Monitor AI mentions at scale
Avalyn Pharma
What AI says about Avalyn Pharma
Avalyn Pharma is dedicated to developing inhaled medicines for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company aims to enhance the efficacy of treatments while minimizing side effects associated with traditional systemic drug delivery.
Is this your brand?
Claim this profile to keep your information accurate and add what's missing.
Not in this profile yet:
Products & Services
Inhaled Therapies
Clinical-stage inhaled formulations targeting rare respiratory diseases, including AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib).
Common Questions
What diseases does Avalyn Pharma target?
Avalyn Pharma focuses on rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
What is the goal of Avalyn's inhaled therapies?
The goal is to deliver effective medicines directly to lung tissue, enhancing efficacy and reducing side effects.
What is Avalyn's current pipeline?
Avalyn's pipeline includes two clinical stage programs, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), along with a preclinical stage program, AP03.
Who leads Avalyn Pharma?
Avalyn is led by a team of experienced executives, including CEO Lyn Baranowski.
Is Avalyn Pharma involved in clinical studies?
Yes, Avalyn Pharma is currently enrolling participants in the MIST PPF Study.